– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a…
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…
Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson…
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
PANProfiler Colon achieved 92.69% positive and 94.05% negative agreement for MSI/dMMR detection Real-world blinded validation on 3178 colorectal cancer patient samplesData…
Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…
HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received…
Accenture, Deloitte, PwC, Huron Consulting Group, Nordic Consulting Partners, Chartis Group, McKinsey & Company, Optum, Clearwater, Cognizant, Salesforce, and Vizient…
Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs…
Oversubscribed Seed Round Accelerates Nasdepi®'s Journey as the First Dry Powder Nasal, Heat-Stable Treatment for Anaphylaxis RALEIGH, NORTH CAROLINA /…